Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity
Mikrobielle Vitaminbiosynthese verknüpft Veränderungen der Darmmikrobiota mit Toxizität unter Chemotherapie
mBio · 11.06.2025 · 16 (6)
DOI: 10.1128/mbio.00930-25 ↗Auf einen Blick
Bei 56 Patient:innen mit fortgeschrittenem kolorektalem Karzinom veränderte Capecitabin die Darmmikrobiota und reicherte Gene der Menaquinol-(Vitamin-K2)-Biosynthese an. Höhere Menaquinol-Gene und -Metabolite waren mit weniger peripherer sensorischer Neuropathie verbunden.
Fragestellung
Wie beeinflusst Capecitabin die Darmmikrobiota und stehen mikrobielle Vitamin-K2-Signale mit Toxizität zusammen?
Methode
Längsschnittliche metagenomische Stuhl-Analyse bei 56 Patient:innen mit fortgeschrittenem kolorektalem Karzinom; ergänzend Transposon-Screens, Gendeletionen und Mediumsupplementierung.
Ergebnisse
Capecitabin veränderte das Mikrobiom signifikant und reicherte Menaquinol-Biosynthesegene an. In Experimenten schützte Menaquinol Escherichia coli vor Arzneitoxizität. Modelle sagten Toxizitäten in einer unabhängigen Kohorte voraus.
Schlussfolgerung der Autor:innen
Die Autor:innen folgern, dass behandlungsassoziierte Zunahmen der mikrobiellen Vitaminbiosynthese bakterielle und Wirtszellen vor Toxizität schützen und eine Basis für weitere Mechanismen- und Interventionsstudien bieten.
Kernaussagen
- 56 Patient:innen mit fortgeschrittenem kolorektalem Karzinom unter Capecitabin
- Mehr Menaquinol-(Vitamin-K2)-Biosynthesegene im Stuhl
- Mikrobielle Daten sagten Toxizitäten in unabhängiger Kohorte voraus
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift mBio, erschienen am 11.06.2025. Verfasst von Lars E Hillege und 21 weiteren Autor:innen. Beteiligte Einrichtung: GROW-Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, Limburg, the Netherlands. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Colorectal Neoplasms, Capecitabine, Vitamin K 2. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS, NIDDK NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Dose-limiting toxicities pose a major barrier to cancer treatment. While preclinical studies show that the gut microbiota influences and is influenced by anticancer drugs, data from patients paired with careful side effect monitoring remains limited. Here, we investigate capecitabine (CAP)-microbiome interactions through longitudinal metagenomic sequencing of stool from 56 advanced colorectal cancer patients. CAP significantly altered the gut microbiome, enriching for menaquinol (vitamin K2) biosynthesis genes. Transposon library screens, targeted gene deletions, and media supplementation revealed that menaquinol biosynthesis protects Escherichia coli from drug toxicity. Stool menaquinol gene and metabolite levels were associated with decreased peripheral sensory neuropathy. Machine learning models trained in this cohort predicted toxicities in an independent cohort. Taken together, these results suggest treatment-associated increases in microbial vitamin biosynthesis serve a chemoprotective role for bacterial and host cells. Further, our findings provide a foundation for in-depth mechanistic dissection, human intervention studies, and extension to other cancer treatments. IMPORTANCE Side effects are common during the treatment of cancer. The trillions of microbes found within the human gut are sensitive to anticancer drugs, but the effects of treatment-induced shifts in gut microbes for side effects remain poorly understood. We profiled gut microbes in colorectal cancer patients treated with capecitabine and carefully monitored side effects. We observed a marked expansion in genes for producing vitamin K2 (menaquinone). Vitamin K2 rescued gut bacterial growth and was associated with decreased side effects in patients. We then used information about gut microbes to develop a predictive model of drug toxicity that was validated in an independent cohort. These results suggest that treatment-associated increases in bacterial vitamin production protect both bacteria and host cells from drug toxicity, providing new opportunities for intervention and motivating the need to better understand how dietary intake and bacterial production of micronutrients like vitamin K2 influence cancer treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GROW-Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, Limburg, the Netherlands.
- Department of Surgery, Maastricht University Medical Center+, Maastricht, Limburg, the Netherlands.
- Department of Microbiology and Immunology, University of California San Francisco, San Francisco, California, USA.
- USDA Human Nutrition Research Center on Aging, Tufts University, Medford, Massachusetts, USA.
- Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center+, Maastricht, Limburg, the Netherlands.
- Department of Medical Oncology, Catharina Hospital, Eindhoven, North Brabant, the Netherlands.
ORCID-Profile: Kai R Trepka, Janine Ziemons, Peter J Turnbaugh
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- NIDDK NIH HHS
- U.S. Department of Agriculture
- NIGMS NIH HHS
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Heart, Lung, and Blood Institute
Zitieren
APA
Hillege, L. E., Trepka, K. R., Guthrie, B. G. H., Fu, X., Aarnoutse, R., Paymar, M. R., Olson, C., Zhang, C., Ortega, E., Ramirez, L., de Vos-Geelen, J., Valkenburg-van Iersel, L., van Hellemond, I. E. G., Baars, A., Vestjens, J. H. M. J., Penders, J., Deutschbauer, A., Atreya, C. E., Kidder, W. A., …, & Turnbaugh, P. J. (2025). Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity. mBio, 16(6). https://doi.org/10.1128/mbio.00930-25
Vancouver
Hillege LE, Trepka KR, Guthrie BGH, Fu X, Aarnoutse R, Paymar MR, et al. Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity. mBio. 2025;16(6). doi:10.1128/mbio.00930-25
BibTeX
@article{Hillege2025,
author = {Hillege, Lars E and Trepka, Kai R and Guthrie, Benjamin G H and Fu, Xueyan and Aarnoutse, Romy and Paymar, Maia R and Olson, Christine and Zhang, Chen and Ortega, Edwin and Ramirez, Lorenzo and de Vos-Geelen, Judith and Valkenburg-van Iersel, Liselot and van Hellemond, Irene E G and Baars, Arnold and Vestjens, Johanna H M J and Penders, John and Deutschbauer, Adam and Atreya, Chloe E and Kidder, Wesley A and Smidt, Marjolein L and Ziemons, Janine and Turnbaugh, Peter J},
title = {Microbial vitamin biosynthesis links gut microbiota dynamics to chemotherapy toxicity},
journal = {mBio},
year = {2025},
volume = {16},
number = {6},
doi = {10.1128/mbio.00930-25}
}
EUVIMED